Peter Kaufman
Director, Sponsored Clinical Research, University of Vermont Cancer Center • UVM Institutional PI, Alliance for Clinical Trials in Oncology · Robert Larner College of Medicine
Credentials: · · · · ·
History
PresentSponsored Clinical Research · Robert Larner College of Medicine
- 1987–1989
Medical Oncology
1986–1987
Research
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
New England Journal of Medicine · 2005 · 4,152 citations
Journal of Clinical Oncology · 2017 · 1,358 citations
JAMA Oncology · 2020 · 818 citations
- EP
17 papers
16 papers
14 papers
- DY
13 papers
- AB
11 papers
- SM
11 papers
- WW
11 papers
10 papers
Clinical trials
- 2022
Principal investigator · Withdrawn · Phase 1, Phase 2
MedSIR
- 2019–2021
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Principal investigator · Terminated · Phase 3
Spexis AG
- 1999
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
Study chair · Completed · Phase 1
Dartmouth-Hitchcock Medical Center
- 2026–2029
Site PI · Recruiting · Phase 2
Eli Lilly and Company